INFLAM-X
- Manufacturer
- Gensco Laboratories, LLC
- Effective date
- 2013-05-01
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:04:40
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
WARNINGS SECTION
FOR EXTERNAL USE ONLY AVOID CONTACT WITH EYES
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN
OTC - ACTIVE INGREDIENT SECTION
ACTIVE INGREDIENTS
Aconitum Napellus 3X, Arnica Montana 3X, Belladonna 4X, Bellis Perennis 1X, Calendula Officinalis 1X, Chamomilla 1X, Echinacea Angustifolia 1X, Echinacea Purpurea 1X, Hamamelis Virginiana 1X, Hypericum Perforatum 1X, Millefolium 1X, Symphytum Officinale 3X, Zingiber Officinale 1X.
INACTIVE INGREDIENT SECTION
INACTIVE INGREDIENTS
Purified water, Isopropyl Myristate, lecithin, Urea, Docusate Sodium, Sodium Hydroxide
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 35781-0230-0
WWW.GENSCOLABS.COM
INDICATIONS & USAGE SECTION
INFLAM-X PRO is a homeopathic topical analgesic gel that contains the ingredients listed below. Homeopathic ingredients
have been used since the inception of this science and remain as an effective method of treating select conditions.It is an amber colored odorless gel for use externally to control inflammation and reduce pain.
WARNINGS AND PRECAUTIONS SECTION
For external use only. Do not ingest INFLAM-X PRO and avoid contact with the eyes and mucous membranes, wounds, and damaged skin. If condition worsens, or if symptoms persist for more than seven days or clear up and occur again within a few days, you should consult a doctor. If a rash develops, you should discontinue use until rash clears. After the disappearance of rash, you can try INFLAM-X PRO again on a test area and monitor the site for additional results. If no rash or redness results, then you can resume use. However, if the rash persists or redevelops, use should be discontinued.
Keep this product out of reach of children and seek medical help or contact a Poison Control Center immediately if swallowed.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - ACTIVE INGREDIENT SECTION
| DRUG FACTS | PURPOSE |
|---|---|
| Aconitum Napellus 3X-HPUS | Neuralgia |
| Arnica Montana 3X-HPUS | Healing of Injured Tissue |
| Belladonna 4X-HPUS | Inflammation |
| Bellis Perennis TINC-HPUS | Bruising and Edema |
| Calendula Officinallis TINC-HPUS | Analgesia |
| Chamomilla TINC-HPUS | Tissue Healing |
| Echinacea Angustifolia TINC-HPUS | Inflammation |
| Echinacea Purpurea TINC-HPUS | Inflammation |
| Hamamellis Virginiana TINC-HPUS | Hematomas |
| Hypericum Perforatum TINC-HPUS | Neuropathic Pains |
| Millefolium TINC-HPUS | Wound healing |
| Symphytum Officinale 4X-HPUS | Neuropathy and Periostitus |
| Zingiber Officinale | Inflammation |
OTC - PURPOSE SECTION
INFLAM-X PRO is indicated for the temporary relief of inflammation and pain from injuries such as sprains, strains,
repetitive use injuries, traumatic edema, general swelling of joints and soft tissue of the hand, wrist, elbow, shoulder, neck, back, knee, ankle, foot and toe. INFLAM-X PRO is also indicated for the reduction of bruising.
WARNINGS SECTION
WARNINGS
For external use only. Do not ingest INFLAM-X PRO and avoid contact with the eyes and mucous membranes, wounds, and damaged skin. If condition worsens, or if symptoms persist for more than seven days or clear up and occur again within a few days, you should consult a doctor. If a rash develops, you should discontinue use until rash clears. After the disappearance of rash, you can try INFLAM-X PRO again on a test area and monitor the site for additional results. If no rash or redness results, then you can resume use. However, if the rash persists or redevelops, use should be discontinued.
Keep this product out of reach of children and seek medical help or contact a Poison Control Center immediately if swallowed.
DOSAGE & ADMINISTRATION SECTION
Apply a thin layer (1 drop covers an area of skin 2 inches by 2 inches) to the affected area of the skin 3-4 times daily and rub in gently. Applications of less than 3-4 times a day will not produce optimum results. Excess drops may be wiped from the area. Safe to use on children over age of 2 years.
INFORMATION FOR PATIENTS SECTION
Other Information
Store at room temperature
INACTIVE INGREDIENT SECTION
Inactive Ingredients
Purified water, Isopropyl Myristate, Lecithin, Urea, Docusate Sodium
OTC - QUESTIONS SECTION
Questions? Toll Free 1-866-608-6284 Mon-Fri 9AM to 5PM (EST)
INFORMATION FOR PATIENTS SECTION
Manufactured for
Gensco Laboratories, LLC
Miramar, FL 33027
866.608.6284
US Patent # 5,654,337
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 35781-0230-0 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-6a33-f424-e053-dadaa90a57ce | Inflam-X |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 35781-0230-0 | INFLAM-X | 6 mL in 1 TUBE | GEL | 6 | 1 | |
| 35781-0230-0 | INFLAM-X | 1 in 1 BOX | GEL | 1 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 35781-0230 | INFLAM-X (ACONITUM NAPELLUS, ARNICA MONTANA, BELLADONNA, BELLIS PERENNIS, CALENDULA OFFICINALLIS, CHAMOMILLA, ECHINACEA ANGUSTIFOLIA, ECHINACEA PURPUREA, HAMAMELLIS VIRGINIANA, HYPERICUM PERFORATUM, MILLEFOLIUM, SYMPHYTUM OFFICINALE, ZINGIBER OFFICINALE) GEL [GENSCO LABORATORIES, LLC] | 1 | Legacy NDC, 2 package rows | 20130607_eae51745-f889-409a-ace6-86f3ca5d21d3.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACHILLEA MILLEFOLIUM | ACTIVE INGREDIENT | 2FXJ6SW4PK | 1 | |
| ACONITUM NAPELLUS | ACTIVE INGREDIENT | U0NQ8555JD | 1 | |
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 1 | |
| ATROPA BELLADONNA | ACTIVE INGREDIENT | WQZ3G9PF0H | 1 | |
| BELLIS PERENNIS | ACTIVE INGREDIENT | 2HU33I03UY | 1 | |
| CALENDULA OFFICINALIS FLOWER | ACTIVE INGREDIENT | P0M7O4Y7YD | 1 | |
| CHAMOMILE | ACTIVE INGREDIENT | FGL3685T2X | 1 | |
| COMFREY ROOT | ACTIVE INGREDIENT | M9VVZ08EKQ | 1 | |
| ECHINACEA ANGUSTIFOLIA | ACTIVE INGREDIENT | VB06AV5US8 | 1 | |
| ECHINACEA PURPUREA | ACTIVE INGREDIENT | QI7G114Y98 | 1 | |
| GINGER | ACTIVE INGREDIENT | C5529G5JPQ | 1 | |
| HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK | ACTIVE INGREDIENT | T7S323PKJS | 1 | |
| HYPERICUM PERFORATUM | ACTIVE INGREDIENT | XK4IUX8MNB | 1 | |
| ACHILLEA MILLEFOLIUM | ACTIVE MOIETY | 2FXJ6SW4PK | 1 | |
| ACONITUM NAPELLUS | ACTIVE MOIETY | U0NQ8555JD | 1 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 1 | |
| ATROPA BELLADONNA | ACTIVE MOIETY | WQZ3G9PF0H | 1 | |
| BELLIS PERENNIS | ACTIVE MOIETY | 2HU33I03UY | 1 | |
| CALENDULA OFFICINALIS FLOWER | ACTIVE MOIETY | P0M7O4Y7YD | 1 | |
| CHAMOMILE | ACTIVE MOIETY | FGL3685T2X | 1 | |
| COMFREY ROOT | ACTIVE MOIETY | M9VVZ08EKQ | 1 | |
| ECHINACEA ANGUSTIFOLIA | ACTIVE MOIETY | VB06AV5US8 | 1 | |
| ECHINACEA PURPUREA | ACTIVE MOIETY | QI7G114Y98 | 1 | |
| GINGER | ACTIVE MOIETY | C5529G5JPQ | 1 | |
| HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK | ACTIVE MOIETY | T7S323PKJS | 1 | |
| HYPERICUM PERFORATUM | ACTIVE MOIETY | XK4IUX8MNB | 1 | |
| DOCUSATE SODIUM | INACTIVE INGREDIENT | F05Q2T2JA0 | 1 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 1 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| UREA | INACTIVE INGREDIENT | 8W8T17847W | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- INFLAM-X
- Aconitum Napellus, Arnica Montana, Belladonna, Bellis Perennis, Calendula Officinallis, Chamomilla, Echinacea Angustifolia, Echinacea Purpurea, Hamamellis Virginiana, Hypericum Perforatum, Millefolium, Symphytum Officinale, Zingiber Officinale
- ACONITUM NAPELLUS
- ARNICA MONTANA
- ATROPA BELLADONNA
- BELLIS PERENNIS
- CALENDULA OFFICINALIS FLOWER
- CHAMOMILE
- ECHINACEA ANGUSTIFOLIA
- ECHINACEA PURPUREA
- HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK
- HYPERICUM PERFORATUM
- ACHILLEA MILLEFOLIUM
- COMFREY ROOT
- GINGER
- WATER
- ISOPROPYL MYRISTATE
- UREA
- DOCUSATE SODIUM
- SODIUM HYDROXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 35781-0230 | 35781-0230-0 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SUBCONJUNCTIVAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVESICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | TABLET, EXTENDED RELEASE / ORAL | 13 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / TRANSDERMAL | 472 mg | ||
| UREA | UREA | 8W8T17847W | INSERT / VAGINAL | 50 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / EXTRACORPOREAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE / ORAL | 60 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAVITREAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | POWDER, FOR SUSPENSION / ORAL | 9 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | JELLY / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAVITREAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 7.01 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAPLEURAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | PASTE / DENTAL | 0.6 %w/w | ||
| DOCUSATE SODIUM | DOCUSATE SODIUM | F05Q2T2JA0 | CAPSULE / ORAL | 8.2 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRA-AMNIOTIC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / VAGINAL | 50 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | FILM, SOLUBLE / ORAL | 11 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / TOPICAL | 213 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | TABLET, FILM COATED / ORAL | 8 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | FILM, EXTENDED RELEASE / TRANSDERMAL | 0.85 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SPRAY / TOPICAL | 3665 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, COATED / ORAL | 0.08 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INFILTRATION | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRACARDIAC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SYRUP / ORAL | 71 mg/5ml | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL, METERED / TRANSDERMAL | 350 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAMUSCULAR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, DELAYED RELEASE / ORAL | 0.25 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| DOCUSATE SODIUM | DOCUSATE SODIUM | F05Q2T2JA0 | TABLET, COATED / ORAL | 1 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / TOPICAL | 65000 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / OPHTHALMIC | 0.05 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CREAM, AUGMENTED / TOPICAL | 6 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 27 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | MOUTHWASH / BUCCAL | 2 mg/1ml | ||
| DOCUSATE SODIUM | DOCUSATE SODIUM | F05Q2T2JA0 | TABLET, FILM COATED / ORAL | 6 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | DISC / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CONCENTRATE / ORAL | 10 mg/5ml | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRACAUDAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTABLE, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / AURICULAR (OTIC) | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / PARENTERAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / TOPICAL | 0.2 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRATUMOR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SUBCUTANEOUS | 31.45 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ab5093da-fe6e-437f-94bd-d233a3683967 | eae51745-f889-409a-ace6-86f3ca5d21d3 | 2013-05-01 | Warnings | ab5093da-fe6e-437f-94bd-d233a3683967 eae51745-f889-409a-ace6-86f3ca5d21d3 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.


